MTOR and pancreatic neuroendocrine tumor: Recently, the FDA approved a few targeted agents for pancreatic NETs including sunitinib, a multi-tyrosine kinase inhibitor, and everolimus, an inhibitor of the PI3K-Akt-mTOR signal pathway [8].